Evidence map›Paper›PMID 42633244›Full record

ArticleiScience2026

Prognostic impact of circulating tumor

Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hiroki OsumiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Eiji ShinozakiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Yoshiaki NakamuraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Taito EsakiDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Hiroya TaniguchiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Hironaga SatakeDepartment of Medical Oncology, Kochi Medical School, Kochi, Japan.
Yu SunakawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Yoshito KomatsuDepartment of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan.
Yoshinori KagawaDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Tadamichi DendaDivision of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
Manabu ShiozawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Taroh SatohPalliative and Supportive Care Center, Osaka University Hospital, Suita, Japan.
Tomohiro NishinaDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
Naoki TakahashiDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Takeshi KatoDepartment of Surgery, NHO Osaka National Hospital, Osaka, Japan.
Hideaki BandoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kensei YamaguchiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-treatment alterations in circulating tumor DNA (ctDNA) hold potential for refining treatment strategies in metastatic colorectal cancer (mCRC). In this multi-institutional study of 1,391 patients from the SCRUM-Japan GOZILA platform, we evaluated the prognostic significance of post-treatment rat sarcoma viral oncogene homolog (

Indexed as

circulating tumor DNAmetastatic colorectal cancerNeoBRAFNeoRASoverall survival

Identifiers

PMID42633244
PMCPMC13499150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.